International Journal on Science and Technology (IJSAT)
E-ISSN: 2229-7677 ● Website: www.ijsat.org ● Email: editor@ijsat.org

Mitigating the Molecular Threat: A Review of Carcinogenic and Mutagenic Agents in Pharmaceuticals

Rashmita K Akkatangerhal[1], Panchaxari M. Dandagi[2]

[1]M.Pharm, [2]Head and Professor

[1, 2]Department of Pharmaceutics, KLE College of Pharmacy, KLE Academy of Higher Education and Research, Nehru Nagar, Belagavi, Karnataka, India 590010

Abstract

The safety of pharmaceutical products is a critical concern in drug development, particularly regarding their potential to induce carcinogenicity and mutagenicity. Carcinogenic and mutagenic agents may be present as active ingredients, degradation products, or manufacturing-related impurities, posing significant risks to patient health. This review provides a comprehensive analysis of the mechanisms by which pharmaceutical substances can induce genetic damage, with particular attention to DNA damage, epigenetic modifications, and reactive metabolite formation. It also compares genotoxic and non-genotoxic pathways of carcinogenesis and highlights common high-risk agents such as alkylating compounds, topoisomerase inhibitors, and nitrosamines. Emphasis is placed on global regulatory frameworks, including ICH M7 and related FDA and EMA guidelines, which mandate rigorous risk assessment and impurity control. The review further explores analytical tools such as in vitro and in vivo assays, high-throughput screening, and in silico predictive models used to evaluate genotoxic potential. Finally, current and emerging mitigation strategies are discussed, ranging from process optimization to AI-driven compound design and international regulatory harmonization. These insights aim to inform safer pharmaceutical development by preventing harmful genetic interactions and ensuring long-term patient safety.

Keywords: Carcinogenicity, Mutagenicity, Genotoxic impurities, Pharmaceutical safety, DNA damage, Epigenetic alterations

INTRODUCTION

Pharmaceutical safety is a critical component of drug development, focused on ensuring that medications do not cause unacceptable harm to patients. This includes evaluating both acute and long-term effects, such as genotoxicity and carcinogenicity, which may not be immediately apparent during clinical trials [1]. Over the past decades, several incidents—including the discovery of nitrosamine contaminants in widely used medications—have underscored the importance of stringent safety assessments. Today, safety evaluations are embedded throughout the drug lifecycle, governed by international guidelines such as those from the ICH, and enforced by regulatory agencies worldwide [2]. These efforts aim to not only treat diseases effectively but also to protect patients from hidden toxicological risks.

Carcinogenicity: Carcinogenicity refers to the ability of a substance to cause cancer in living tissues. A carcinogen is any agent—chemical, physical, or biological—that can initiate or promote the transformation of normal cells into cancerous cells. Carcinogens may act by directly damaging DNA (genotoxic carcinogens) or by promoting abnormal cell proliferation through non-genotoxic pathways (e.g., chronic inflammation, hormonal imbalance [3].

Types of carcinogens:

Genotoxic carcinogens cause cancer by directly damaging DNA, leading to mutations. Examples include benzo[a]pyrene and alkylating agents.Non-genotoxic carcinogens do not directly affect DNA, but they promote cancer through other mechanisms, such as hormonal imbalance or chronic inflammation. Examples include some hormones and immunosuppressants [3].

Mutagenicity:Mutagenicity is the ability of a substance to induce genetic mutations—permanent changes in the DNA sequence. A mutagen can cause alterations in genes, chromosomal structures, or the number of chromosomes [4].

Types of mutations:

Point mutations: These are small changes in a single nucleotide base of DNA. For example, one base (A, T, C, or G) is replaced with another, which can alter the function of a gene. Insertions or deletions: These involve the addition (insertion) or loss (deletion) of one or more DNA bases. They can disrupt the genetic code, often causing frameshift mutations that significantly affect protein function [5]. Chromosomal aberrations: These are large-scale structural changes in chromosomes, such as breaks, rearrangements, or changes in number (e.g., duplications, translocations, or aneuploidy), which can lead to major genetic disorders or cancer.Mutations caused by mutagens may lead to cellular dysfunction, developmental abnormalities, or even cancer, making many mutagens potential carcinogens [4].

Relationship Between the Carcinogenicity and Mutagenicity is all genotoxic carcinogens are mutagens, but not all mutagens are necessarily carcinogens.Mutagenicity is often used as a screening tool to identify potentially carcinogenic compounds early in drug development [5].

Importance of Identifying and Mitigating Genotoxic Agents in Pharmaceuticals

Genotoxic agents are substances capable of damaging cellular genetic material, which can result in mutations, chromosomal abnormalities, and an increased risk of cancer. In the pharmaceutical sector, the presence of genotoxic impurities (GTIs) or active pharmaceutical ingredients with genotoxic properties represents a significant safety concern, particularly for medications intended for prolonged or chronic administration [6]. These impurities can arise from various sources during drug synthesis, including starting materials, intermediates, by-products, reagents, catalysts, and degradation products formed during storage or handling. Because even very low levels of genotoxic impurities can cause harmful genetic alterations, it is critical to identify, monitor, and control these impurities to ensure patient safety. Regulatory guidelines such as ICH M7 emphasize comprehensive risk assessment and implementation of control strategies—like process optimization and purification—to minimize the presence of genotoxic impurities in pharmaceutical products [7]

1. Risk of Mutations and Cancer:Uncontrolled exposure to genotoxic agents can cause mutations that may trigger the development of cancer. This risk is particularly unacceptable in medications that are otherwise considered safe, especially when used by vulnerable groups such as pediatric, geriatric, or chronic patients. Because even minimal DNA damage from genotoxic substances can potentially lead to carcinogenesis, strict control and minimization of such exposures in pharmaceuticals are essential to protect these sensitive populations [6]

2. Regulatory Mandates: Pharmaceutical regulatory bodies worldwide, such as the ICH, FDA, and EMA, require drug manufacturers to assess, manage, and restrict the presence of genotoxic impurities in their products. The ICH M7 guideline specifically provides a detailed approach for evaluating and controlling DNA-reactive impurities in pharmaceuticals to reduce the risk of cancer. This guideline offers a practical framework for identifying, categorizing, and limiting mutagenic impurities, ensuring patient safety by setting acceptable exposure limits and recommending appropriate control measures throughout drug development and manufacturing processes [8].

3. Past Incidents and Lessons Learned: Instances of nitrosamine contamination in angiotensin receptor blocker (ARB) medications, such as valsartan and losartan, have revealed the tangible dangers posed by genotoxic impurities. These contamination events prompted widespread global recalls of affected drug batches, underscoring the critical importance of ongoing monitoring and stringent quality control in pharmaceutical manufacturing. The recalls highlighted vulnerabilities in supply chains and manufacturing processes that allowed carcinogenic nitrosamines, like N-nitrosodimethylamine (NDMA) and N-Nitroso-N-methyl-4-aminobutyric acid (NMBA), to enter medications used by millions of patients worldwide. These incidents have driven regulatory agencies to enforce stricter oversight and testing protocols to prevent similar occurrences in the future and protect patient safety [2]

4. **Patient Safety and Public Health:** Even minimal amounts of highly potent genotoxic substances can pose significant long-term health risks, such as an elevated likelihood of developing cancer. Consequently, it is crucial to implement early detection, thorough testing, and effective control measures to ensure that the benefits of pharmaceutical products continue to outweigh their potential risks. These proactive steps help safeguard patient health by minimizing exposure to harmful genetic toxins throughout the drug development and manufacturing process[9].

The primary objective of this review is to provide a comprehensive overview of carcinogenic and mutagenic agents in pharmaceutical substances and to discuss the strategies and technologies used to mitigate these risks. This includes both active pharmaceutical ingredients (APIs) and impurities that may form during drug synthesis, storage, or degradation[9].

The review aims to summarize the mechanisms by which pharmaceutical agents cause carcinogenicity or mutagenicity. Highlight common genotoxic agents and contamination cases in drug products. Discuss regulatory guidelines and risk assessment frameworks. Explore analytical methods and mitigation strategies to reduce genotoxic risk in drug development and manufacturing.

MECHANISMS OF CARCINOGENICITY AND MUTAGENICITY

DNA damage refers to alterations in the DNA structure that can disrupt its normal function. It can occur due to endogenous factors (e.g., reactive oxygen species, metabolic by-products) or exogenous sources

such as mutagenic drugs, radiation, or chemical contaminants.If not properly repaired, this damage can lead to mutations, which are often the initiating events for carcinogenesis[10].

Importance in Carcinogenicity and Mutagenicity

DNA damage is a critical initiating event in:

Mutagenesis: If damaged DNA is mis repaired, it may introduce mutations[6].

Carcinogenesis: Accumulated mutations in oncogenes or tumor suppressor genes can lead to cancer.Genotoxic pharmaceutical agents like alkylating agents, topoisomerase inhibitors, and nitrosamines often exert their toxicity by inducing DNA lesions[7].

Major DNA Repair Mechanisms

Repair Pathway	Function	Key Proteins/ Enzymes
Base Excision Repair (BER) [10]	Repairs small, non-bulky lesions like oxidative and alkylated bases	DNA glycosylases, APE1
Nucleotide Excision Repair (NER) [11]	Removes bulky lesions and helix-distorting damage (e.g., UV-induced dimers)	XPA, XPB, XPD
Mismatch Repair (MMR) [12]	Corrects base–base mismatches and small insertion–deletion loops	MLH1, MSH2
Homologous Recombination (HR) [13]	Error-free repair of double-strand breaks using a homologous template	BRCA1/2, RAD51, KU70/80
Non-Homologous End Joining (NHEJ) [13]	Quick but error-prone repair of double-strand breaks	BRCA1/2, RAD51, KU70/80

Some chemotherapeutic drugs deliberately induce DNA damage (e.g., cisplatin, doxorubicin) to kill cancer cells. However, if DNA repair fails or is error-prone, this can cause:Mutations in normal cells, Secondary malignancies, Heritable genetic alterations. Hence, understanding DNA damage and repair is crucial forDesigning safer drugs, predicting genotoxic risks, Developing DNA repair-targeted therapies

Epigenetic Alterations in Carcinogenicity and Mutagenicity

Epigenetic alterations are heritable changes in gene expression that occur without changes to the DNA sequence. These changes regulate how genes are turned on or off and are crucial for normal cell function. Key epigenetic mechanisms includeDNA methylation, Histone modification, Non-coding RNA regulation[14]

Epigenetics and Carcinogenicity: Epigenetic dysregulation is a hallmark of cancer. Even without DNA mutations, epigenetic changes can activate oncogenes or silence tumor suppressor genes, promoting tumor initiation and progression.

Examples:Hypermethylation of promoter regions of tumor suppressor genes like p16, MLH1, and BRCA1 → Gene silencing, Global hypomethylation → Genomic instability, Aberrant histone acetylation → Altered chromatin structure and gene expression [15].

Some pharmaceutical agents may cause epigenetic alterations without directly damaging DNA, classifying them as non-genotoxic carcinogens. This makes them harder to detect using traditional mutagenicity assays.Drugs like valproic acid and azacitidine act on histone deacetylases (HDACs) and DNA methyltransferases (DNMTs), respectively.Long-term exposure to certain agents can induce stable epigenetic reprogramming, leading to cancerous transformations [15].

Epigenetics and Mutagenicity:Epigenetics and mutagenicity are distinct but interconnected concepts in the study of how changes in genetic information—or its regulation—can lead to disease, especially cancer. While mutagenicity involves permanent changes to the DNA sequence, epigenetics refers to heritable changes in gene expression without altering the DNA sequence. Importantly, epigenetic modifications can influence genome stability and mutation rates, thus playing a supportive or even initiating role in mutagenesis [16].

Reactive Metabolites and Oxidative Stress: Role in Mutagenicity and Carcinogenicity

Reactive metabolites are chemically reactive intermediates formed during the metabolic processing (usually via liver enzymes like cytochrome P450) of drugs and xenobiotics. These metabolites often contain electrophilic centers that can interact with cellular macromolecules like DNA, RNA, and proteins, leading to adduct formation.Such interactions can cause DNA strand breaks, point mutations, or chromosomal aberrations, initiating mutagenesis or carcinogenesis.For example, acetaminophen overdose leads to the generation of N-acetyl-p-benzoquinone imine (NAPQI), a reactive metabolite responsible for liver toxicity [17]**.**



Oxidative Stress and Its Impact

Oxidative stress occurs when there is an imbalance between the production of reactive oxygen species (ROS) and the body's antioxidant defences. ROS such as superoxide anion, hydrogen peroxide, and hydroxyl radicals are highly reactive and can causeOxidative DNA damage, including base modifications like 8-oxoguanine.Lipid peroxidation, which produces further DNA-reactive aldehydes (e.g., malondialdehyde).Activation of inflammatory pathways, which may further generate mutagenic agents.Chronic oxidative stress is a well-known contributor to carcinogenesis and genomic instability [18].

How Reactive Metabolites and ROS Contribute to Mutagenicity [19]

DNA Adduct Formation: Covalent binding of reactive metabolites to DNA can lead to mispairing or replication errors.

Interference with DNA Repair: Some reactive metabolites can inhibit DNA repair enzymes, increasing mutagenic risk.

ROS-Induced Base Damage: ROS frequently oxidize guanine to 8-oxoguanine, which can pair with adenine instead of cytosine, causing G:C → T: A transversions

Comparison between Genotoxic and Non-Genotoxic Carcinogens

Feature	**Genotoxic Carcinogens [20]**	**Non-Genotoxic Carcinogens [21]**
Definition	Directly damage DNA and induce mutations	Do not directly damage DNA; promote cancer via indirect mechanisms
Mechanism of Action	DNA adduct formation, strand breaks, chromosomal changes	Epigenetic changes, hormonal imbalances, oxidative stress
Mutation Induction	Yes	No
Examples	Aflatoxin B1, Benzo[a]pyrene, Cyclophosphamide	Phenobarbital, TCDD (dioxin), Peroxisome proliferators
Detection Methods	Ame's test, Comet assay, Micronucleus test	Long-term bioassays, epigenetic profiling, mechanistic studies
Carcinogenic Pathways	Initiates cancer through genetic mutations	Promotes cancer via cell proliferation, inflammation, receptor modulation
Regulatory Concern	Often restricted or banned	Require detailed weight-of-evidence assessment
Latency Period	Often shorter due to direct DNA damage	Typically, longer due to indirect action
Reversibility	Irreversible DNA mutations	Sometimes reversible upon cessation of exposure

COMMON CARCINOGENIC AND MUTAGENIC AGENTS INPHARMACEUTICALS

Pharmaceuticals may exert mutagenic or carcinogenic effects either as intended therapeutic agents (especially in oncology) or through unintended impurities or metabolites. The key groups involved include alkylating agents, antimetabolites, topoisomerase inhibitors, impurities like nitrosamines, and reactive drug metabolites.[23]

1. Alkylating Agents: Alkylating agents transfer alkyl groups to DNA bases, particularly at the N7 position of guanine, causing cross-linking, mispairing, or DNA strand breaks. These drugs are effective anticancer agents but carry high genotoxic and carcinogenic potential.[24]

- Example: *Cyclophosphamide*, used for chemotherapy and immunosuppression.
- Carcinogenic Risk: Known to increase the risk of secondary cancers such as leukemia and bladder cancer.

2. Antimetabolites: These agents mimic normal cellular metabolites, disrupting DNA and RNA synthesis during replication. Although useful in cancer treatment, prolonged exposure can induce mutations and chromosomal damage.[25]

- Example: *Methotrexate*, an antifolate used in cancer and autoimmune disorders.
- Mechanism: Inhibits dihydrofolate reductase → disrupts nucleotide synthesis → DNA replication errors.

3. Topoisomerase Inhibitors: These drugs interfere with DNA topoisomerases, enzymes that manage DNA supercoiling. Inhibiting these enzymes leads to DNA strand breaks and mutagenesis.[26]

- Example: *Doxorubicin* (Topoisomerase II inhibitor).
- Concern: Risk of therapy-related acute myeloid leukemia (t-AML) due to chromosomal translocations.

4. Contaminants and Impurities: Nitrosamines such as *N-nitrosodimethylamine (NDMA)* and *N-nitrosodiethylamine (NDEA)* are potent mutagens found as impurities in drug manufacturing. These are classified as probable human carcinogens.[25]

- Example: Detected in contaminated batches of *valsartan*, *ranitidine*, and *metformin*.
- Mechanism: Metabolic activation leads to alkylating intermediates that form DNA adducts.

5. Drug Metabolites with Genotoxic Potential: Some drugs are not inherently genotoxic, but their metabolites may be. These metabolites can become reactive intermediates, capable of forming DNA adducts or oxidative damage.[24]

- Example: *Tamoxifen* is metabolized to DNA-reactive intermediates in the liver.
- Effect: Associated with an increased risk of endometrial cancer.

Several pharmaceutical agents exhibit mutagenic or carcinogenic properties, either as part of their therapeutic mechanism or due to unintended impurities. Alkylating agents, antimetabolites, and topoisomerase inhibitors are widely used in oncology but carry substantial genotoxic risks. Meanwhile, contaminants like nitrosamines and drug metabolites with genotoxic potential highlight the need for rigorous quality control and long-term safety monitoring.

SOURCES OF CARCINOGENIC AND MUTAGENIC AGENTS IN PHARMACEUTICALS

Carcinogenic and mutagenic risks in pharmaceuticals may arise from various stages of drug development, production, and storage. These risks are typically grouped into three main categories: active pharmaceutical ingredients (APIs), impurities/contaminants, and formulation or packaging-related interactions [27]**.**

1. API-Related Risks[28]

Some active pharmaceutical ingredients themselves possess carcinogenic or mutagenic properties, either as part of their mechanism of action (especially in cancer therapy) or due to long-term toxicological effects.

▪ Antineoplastic Agents

Chemotherapy drugs such as alkylating agents, topoisomerase inhibitors, and antimetabolites are designed to target DNA replication in rapidly dividing cells. However, they often lack selectivity and can damage healthy DNA, leading to secondary malignancies such as leukemia or bladder cancer.Example: Cyclophosphamide is a well-known genotoxic carcinogen.

▪ Certain Antibiotics and Antivirals

Some antibiotics (e.g., rifampin) and antivirals (e.g., zidovudine) have shown mutagenic or clastogenic effects in vitro or in animal studies. Zidovudine, for example, integrates into host DNA and has been linked to chromosomal instability.

2. Impurities and Contaminants[29]

Pharmaceutical products may contain impurities arising from the manufacturing process, degradation, or storage conditions. Several of these impurities are highly mutagenic or carcinogenic.

▪ Nitrosamines (e.g., NDMA, NDEA) [31]

Nitrosamines are classified as probable human carcinogens (Group 2A, IARC). They are formed by the reaction of amines and nitrite under acidic or high-temperature conditions and have been detected in drugs like valsartan, ranitidine, and metformin.

- NDMA and NDEA are known to induce DNA alkylation, resulting in mutations and cancer in animals.

▪ Residual Solvents, Reagents, and Degradation Products

- Unreacted reagents or toxic solvents (e.g., benzene, chloroform) may remain in the final product. Additionally, drug degradation (due to moisture, heat, or light) can generate mutagenic by-products.

3. Formulation and Packaging Interactions[30]

Interactions between the drug and excipients, or leakable from packaging materials (e.g., plastics, rubber), can generate reactive compounds that have carcinogenic potential.

- Phthalates, used as plasticizers, and bisphenol A (BPA) can leach into the drug product and are suspected endocrine disruptors and possible carcinogens.
- Degradation of stabilizers or preservatives in formulations may also yield reactive aldehydes or peroxides.

Carcinogenic and mutagenic agents may enter pharmaceuticals through several routes. Active pharmaceutical ingredients—especially chemotherapeutics and certain antivirals—may exert genotoxic effects. Impurities such as nitrosamines and residual solvents pose significant risks if not adequately

controlled. Additionally, interactions between drugs and excipients or packaging materials may generate reactive species, underscoring the need for stringent quality control at all stages of the drug lifecycle.

TESTING AND DETECTION METHODS FOR CARCINOGENICITY AND MUTAGENICITY

Evaluating the carcinogenic and mutagenic potential of pharmaceuticals is a critical component of drug safety assessment. A combination of in vitro, in vivo, and advanced predictive tools is used to comprehensively detect genotoxicity and carcinogenic risk.A comprehensive assessment of carcinogenic and mutagenic potential in pharmaceuticals involves a tiered approach. In vitro assays like the Ames test and chromosomal aberration assays offer initial screening for genetic toxicity. In vivo studies provide confirmatory evidence within the context of biological systems. Advanced tools such as high-throughput screening, computational QSAR models, and 'omics' technologies further enhance the predictive accuracy and mechanistic insight into chemical-induced carcinogenesis [32]

1. In Vitro Assays[33]:These laboratory-based assays are often the first line of testing and are designed to detect direct interactions between chemicals and genetic material.

▪ Ames Test (Bacterial Reverse Mutation Assay): The Ames test uses strains of *Salmonella typhimurium* or *Escherichia coli* that carry mutations in genes involved in histidine or tryptophan synthesis. Reversion to normal growth indicates mutagenicity.

- Advantages: Cost-effective, rapid, and sensitive to point mutations.
- Limitations: Cannot detect chromosomal damage; requires metabolic activation system (S9 mix) for pro-mutagens.

▪ Chromosomal Aberration Test:This assay identifies structural chromosomal changes in cultured mammalian cells after exposure to the test compound.

- Outcome: Includes chromatid breaks, exchanges, and fragmentations.
- Application: Used to detect clastogenic potential.

2. In Vivo Models[34]:In vivo tests evaluate genetic damage in the context of a living organism, providing insights into absorption, metabolism, and DNA repair mechanisms.

▪ Rodent Carcinogenicity Studies:Long-term studies (up to 2 years) in rats or mice are used to assess the tumorigenic potential of a substance.

- Endpoints: Tumor incidence, organ specificity, dose-response relationships.
- Challenges: High cost, long duration, ethical concerns.

▪ Micronucleus Assay**:** This test detects micronuclei—small, extranuclear bodies in dividing cells—indicating chromosomal breakage or loss.

- In vivo application: Commonly conducted in bone marrow or peripheral blood cells of rodents.

3. Advanced Tools and Modern Approaches[35]:With the evolution of toxicology, modern methods complement traditional assays for better sensitivity and mechanistic understanding.

▪ High-Throughput Screening (HTS):HTS technologies allow simultaneous testing of thousands of compounds against multiple genetic or cellular endpoints using robotics and automation.

- Use case: Early identification of genotoxicity in drug discovery.

▪ In Silico Models (QSAR & SAR):Quantitative Structure–Activity Relationship (QSAR) and Structure–Activity Relationship (SAR) models use chemical structure to predict genotoxic potential[36].

- Benefit: Reduce animal testing and prioritize high-risk compounds.
- Regulatory Use: Widely accepted for preliminary screening by EMA, FDA, and ICH.

▪ 'Omics' Technologies:Genomics, proteomics, and transcriptomics help identify early molecular changes associated with carcinogenesis.

- Genomics: Identifies gene expression changes post-exposure.
- Proteomics: Detects protein modifications linked to DNA repair or apoptosis.

A comprehensive assessment of carcinogenic and mutagenic potential in pharmaceuticals involves a tiered approach. In vitro assays like the Ames test and chromosomal aberration assays offer initial screening for genetic toxicity. In vivo studies provide confirmatory evidence within the context of biological systems. Advanced tools such as high-throughput screening, computational QSAR models, and 'omics' technologies further enhance the predictive accuracy and mechanistic insight into chemical-induced carcinogenesis

REGULATORY FRAMEWORKS AND GUIDELINES FOR CARCINOGENICITY AND MUTAGENICITY IN PHARMACEUTICALS

To ensure the safety of pharmaceutical products, international regulatory agencies have established comprehensive guidelines for evaluating and controlling genotoxic and carcinogenic risks. These frameworks aim to identify harmful compounds early in development and implement control measures during production and quality assurance [37]**.**

1. ICH Guidelines: The International Council for Harmonisation (ICH) provides harmonized technical requirements across major pharmaceutical markets (U.S., EU, Japan). The most relevant ICH guidelines include:

🔷ICH M7(R1): *Assessment and Control of DNA Reactive (Mutagenic) Impurities*

Focuses on mutagenic impurities that may pose a carcinogenic risk.Introduces the Threshold of Toxicological Concern (TTC) concept.Requires control strategies such as QSAR analysis, in vitro testing, and analytical control [8]

ICH S2(R1): *Genotoxicity Testing and Data Interpretation*

Recommends a weight-of-evidence approach combining in vitro and in vivo genotoxicity tests.Includes the Ames test, in vitro chromosome aberration test, and micronucleus test.Ensures that pharmaceuticals do not cause DNA damage at therapeutic doses [22].

ICH Q3A/B: *Impurities in Drug Substances and Products*

Addresses the identification, qualification, and control of impurities (both organic and inorganic).Mutagenic impurities must be addressed in conjunction with ICH M7[8].

2. Perspectives from Regulatory Agencies

🔷US FDA (Food and Drug Administration)

Adopts ICH guidelines and issues specific guidances (e.g., for nitrosamine control). Emphasizes risk-based approaches, TTC, and control strategies.Publishes warning letters and recalls for drugs exceeding genotoxic impurity limits [38].

🔷 EMA (European Medicines Agency)

Follows ICH guidelines and has specific regulatory pathways for genotoxic risk assessment.Implements rapid alerts and recalls (e.g., the valsartan recall due to NDMA).Supports stepwise testing and computational predictions [39].

🔷 PMDA (Japan's Pharmaceuticals and Medical Devices Agency)

Implements all ICH guidelines and supports regional approaches to impurity testing.Promotes the use of QSAR modeling and toxicity databases for early screening [40]

3. Threshold of Toxicological Concern (TTC): TTC is a risk assessment principle used to establish a daily exposure threshold below which there is a very low risk of carcinogenicity.For mutagenic impurities, the default TTC is 1.5 µg/day.Derived from carcinogenic potency data of thousands of chemicals.Useful in situations where no animal data are available [41].

4. Permissible Limits and Control Thresholds: Regulatory bodies define specific acceptance limits for known mutagenic and carcinogenic impurities, based on:Daily intake limits (µg/day), Genotoxicity data and cancer potency, Duration of exposure (e.g., chronic, short-term, or single dose), Control measures: Process design, impurity fate studies, robust analytical methods (e.g., LC-MS/MS)[41].

International regulatory frameworks such as those set by ICH (M7, S2, Q3A/B), and adopted by agencies like the FDA, EMA, and PMDA, form the basis of global control strategies for genotoxic and carcinogenic risks in pharmaceuticals. Central to these frameworks are predictive tools, genotoxicity assays, and the Threshold of Toxicological Concern (TTC), which guides the establishment of permissible exposure limits. These standards ensure that pharmaceutical impurities are managed through rigorous risk assessment and analytical control strategies

MITIGATION STRATEGIES FOR CARCINOGENIC AND MUTAGENIC RISKS IN PHARMACEUTICALS

Given the serious health implications of carcinogenic and mutagenic impurities in drugs, proactive mitigation strategies are essential throughout the drug development lifecycle. These strategies span process chemistry, analytical controls, formulation design, and quality management systems [43].

1. Process Chemistry Optimization[44]:Optimizing synthetic routes is critical to preventing the formation of genotoxic impurities during drug manufacturing.

▪ Avoiding Genotoxic Precursors:Chemists are encouraged to redesign synthetic pathways to avoid reagents or intermediates that could lead to DNA-reactive impurities. For example, amine-nitrite combinations known to form nitrosamines should be eliminated where possible.

▪ Green Chemistry Approaches**:** Adopting green chemistry principles helps minimize hazardous reagents and waste. Catalytic and aqueous-phase reactions often reduce by-products that may have mutagenic potential.

2. Analytical Controls[45]:Detecting impurities at very low levels is essential for risk management, particularly for trace genotoxins.

▪ LC-MS/MS and GC-MS: These advanced techniques are employed for high-sensitivity detection (ppt–ppb levels) of nitrosamines and other genotoxic impurities.

- LC-MS/MS: Suitable for polar and thermally unstable compounds.
- GC-MS: Effective for volatile or semi-volatile impurities.

3. Formulation Design[42]: Pharmaceutical formulation plays a role in preventing degradation and chemical reactions that could lead to mutagenic by-products.

▪ Stabilizing Agents: Adding antioxidants, chelating agents, or pH modifiers can reduce the formation of reactive impurities during storage.

▪ Barrier Packaging: Packaging materials such as aluminium blisters or glass vials limit exposure to moisture, oxygen, and light—factors that promote degradation and impurity formation.

4. Lifecycle Risk Management[43]:Comprehensive risk management systems ensure continuous control of genotoxic risks throughout a drug's lifecycle.

▪ Continuous Monitoring: Routine stability studies and periodic impurity profiling help identify changes in impurity levels over time.

▪ Change Control in Manufacturing: Any changes in raw materials, suppliers, processes, or equipment must be evaluated for potential impact on genotoxic impurity profiles.

5. Nitrosamine Risk Mitigation[44]:Nitrosamines have become a major regulatory focus due to widespread contamination events.

▪ Risk Assessment Framework: Companies are required to conduct comprehensive risk assessments of their products and manufacturing processes to identify potential nitrosamine formation.

▪ Control at Raw Material and Excipient Level:Special attention is given to amines in APIs or excipients, nitrite levels in reagents, and residual solvents, which can participate in nitrosamine formation.

Effective mitigation of carcinogenic and mutagenic risks in pharmaceuticals requires a multifaceted approach. Optimizing chemical synthesis pathways to avoid hazardous intermediates, implementing

sensitive analytical techniques like LC-MS/MS for impurity detection, and enhancing formulation stability through packaging and excipient control are essential strategies. A strong emphasis is placed on lifecycle risk management and proactive control of nitrosamine formation at the raw material level.

FUTURE PERSPECTIVES IN MANAGING CARCINOGENICITY AND MUTAGENICITY IN PHARMACEUTICALS

With evolving scientific tools and increasing regulatory scrutiny, the pharmaceutical industry is shifting towards predictive, proactive, and harmonized approaches to control genotoxic and carcinogenic risks. Key future directions include innovations in toxicology, AI-driven modeling, safer compound design, and global regulatory alignment.

1.Advances in Predictive Toxicology: Predictive toxicology uses computational and mechanistic tools to forecast toxicity based on molecular properties, reducing reliance on animal testing and accelerating decision-making.Toxicogenomic, high-throughput screening, and 3D cell models are increasingly used to detect early molecular changes linked to carcinogenic outcomes.These tools allow for early intervention during drug design and development, preventing late-stage failure.

2. Role of AI and In Silico Models: Artificial intelligence (AI), machine learning (ML), and in silico models are transforming genotoxicity risk prediction.Quantitative structure–activity relationship (QSAR) models and AI-trained toxicity databases help predict mutagenic potential based on chemical structure.AI-driven platforms can simulate metabolic pathways, estimate DNA reactivity, and even suggest safer analogs during early discovery.

3. Development of Safer Drug Analogs: Modern drug development now incorporates structure–toxicity relationships to design non-mutagenic, non-carcinogenic analogs of known therapeutic agents.Rational drug design avoids reactive functional groups and structural alerts associated with genotoxicity.Advances in medicinal chemistry and computer-aided drug design (CADD) are accelerating the creation of safer compounds without compromising efficacy.

4. Harmonization of International Standards: Global collaboration among regulatory authorities aims to streamline genotoxicity testing, standardize impurity thresholds, and promote mutual recognition of data.Organizations like ICH, OECD, FDA, and EMA are aligning on policies such as ICH M7 for mutagenic impurity control.Initiatives like IMI (Innovative Medicines Initiative) and OECD QSAR Toolbox are contributing to the global harmonization of toxicity data.

Future strategies to manage carcinogenicity and mutagenicity in pharmaceuticals are centered around predictive toxicology, AI-powered modeling, and the design of safer chemical analogs. These innovations reduce reliance on traditional animal testing, provide early risk signals, and support the design of inherently safer compounds. Moreover, the harmonization of international regulatory frameworks facilitates consistent and efficient global risk management.

DISCUSSION

The presence of genotoxic and carcinogenic agents in pharmaceutical products remains one of the most challenging aspects of modern drug development. This review underscores that genotoxicity may arise from both intended therapeutic actions—particularly in oncology—and unintended sources such as synthetic impurities, degradation by-products, and packaging interactions. Notably, nitrosamines have

emerged as a critical concern due to their high carcinogenic potency and widespread detection across various drug classes.

A clear understanding of the underlying mechanisms, including DNA damage, epigenetic disruption, and oxidative stress, is essential for designing safer compounds and anticipating potential risks. The comparison between genotoxic and non-genotoxic carcinogens highlights that not all DNA damage results from direct genotoxicity—many compounds exert carcinogenic effects through indirect pathways like epigenetic silencing of tumor suppressor genes.

This review also highlights significant regulatory advances, particularly the ICH M7(R1) guideline, which provides a structured approach for assessing DNA-reactive impurities. Regulatory authorities now emphasize the use of computational models (QSAR), toxicological thresholds (TTC), and mechanistic testing to support early identification and mitigation. However, challenges persist in detecting low-level impurities and predicting long-term risks, particularly for non-genotoxic agents.

The integration of advanced technologies—such as AI-based prediction tools, 3D cell cultures, and omics-based screening—is expected to revolutionize the field by reducing reliance on animal models while improving the accuracy of risk assessments. The development of safer drug analogs using structure–toxicity knowledge and international harmonization of impurity standards are promising steps toward minimizing genotoxic exposures.

CONCLUSION

The threat posed by carcinogenic and mutagenic agents in pharmaceuticals is both significant and evolving. This review highlights the need for a comprehensive, multidisciplinary approach that combines scientific understanding, regulatory compliance, and technological innovation. Mechanistic insights into DNA damage, mutagenesis, and epigenetic changes are essential for anticipating drug-related risks. Rigorous impurity control, supported by sensitive analytical methods and global regulatory guidelines, remains the cornerstone of safety assurance.

Going forward, future efforts must focus on predictive toxicology, AI-enhanced screening models, and the proactive design of non-genotoxic alternatives. Harmonizing international regulatory practices and investing in safer manufacturing technologies will further safeguard patient health. Ultimately, reducing genotoxic and carcinogenic risks in pharmaceuticals is not just a regulatory obligation but a scientific imperative for advancing safe and effective therapeutics.

REFERANCES

1. Cioc RC, Joyce C, Mayr M, Bream RN. Formation of N-nitrosamine drug substance related impurities in medicines: a regulatory perspective on risk factors and mitigation strategies. Organic Process Research & Development. 2023 Jul 21;27(10):1736-50.
2. Tuesuwan B, Vongsutilers V. Nitrosamine contamination in pharmaceuticals: threat, impact, and control. Journal of Pharmaceutical Sciences. 2021 Sep 1;110(9):3118-28.
3. Wogan GN, Hecht SS, Felton JS, Conney AH, Loeb LA. Environmental and chemical carcinogenesis. InSeminars in cancer biology 2004 Dec 1 (Vol. 14, No. 6, pp. 473-486). Academic Press.

4. Mecsas J. Use of signature-tagged mutagenesis in pathogenesis studies. Current opinion in microbiology. 2002 Feb 1;5(1):33-7.
5. Korotchkina LG, Patel MS. Mutagenesis Studies of the Phosphorylation Sites of Recombinant Human Pyruvate Dehydrogenase. SITE-SPECIFIC REGULATION∗. Journal of Biological Chemistry. 1995 Jun 16;270(24):14297-304.
6. Robinson DI. Control of genotoxic impurities in active pharmaceutical ingredients: a review and perspective. Organic Process Research & Development. 2010 Jul 16;14(4):946-59.
7. Humfrey CD. Recent developments in the risk assessment of potentially genotoxic impurities in pharmaceutical drug substances. Toxicological sciences. 2007 Nov 1;100(1):24-8.
8. Guideline IH. Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk M7. InInternational conference on harmonization of technical requirements for registration of pharmaceuticals for human use (ICH): Geneva 2014 Jun 5.
9. Kobets T, Smith BP, Williams GM. Food-borne chemical carcinogens and the evidence for human cancer risk. Foods. 2022 Sep 13;11(18):2828.
10. Hoeijmakers JH. DNA damage, aging, and cancer. New England journal of medicine. 2009 Oct 8;361(15):1475-85.
11. Lindahl T, Barnes DE. Repair of endogenous DNA damage. InCold Spring Harbor symposia on quantitative biology 2000 Jan 1 (Vol. 65, pp. 127-134). Cold Spring Harbor Laboratory Press.
12. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009 Oct 22;461(7267):1071-8.
13. Gonzalgo ML, Jones PA. Mutagenic and epigenetic effects of DNA methylation. Mutation Research/Reviews in Mutation Research. 1997 Apr 1;386(2):107-18.
14. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nature genetics. 2003 Mar;33(3):245-54.
15. Feinberg AP, Tycko B. The history of cancer epigenetics. Nature Reviews Cancer. 2004 Feb 1;4(2):143-53.
16. Ehrlich M. DNA hypomethylation in cancer cells. Epigenomics. 2009 Dec 1;1(2):239-59.
17. Guengerich FP. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chemical research in toxicology. 2001 Jun 18;14(6):611-50.
18. Valko M, Rhodes CJ, Moncol J, Izakovic MM, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chemico-biological interactions. 2006 Mar 10;160(1):1-40.
19. Cooke MS, Evans MD, Dizdaroglu M, Lunec J. Oxidative DNA damage: mechanisms, mutation, and disease. The FASEB journal. 2003 Jul;17(10):1195-214.
20. Luch A. Nature and nurture–lessons from chemical carcinogenesis. Nature Reviews Cancer. 2005 Feb;5(2):113-25.
21. Hernández LG, van Steeg H, Luijten M, van Benthem J. Mechanisms of non-genotoxic carcinogens and importance of a weight of evidence approach. Mutation Research/Reviews in Mutation Research. 2009 Sep 1;682(2-3):94-109.
22. Teasdale A. ICH M7: Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk. ICH Quality Guidelines: An Implementation Guide. 2017 Sep 27:667-99.

23. Thresher A, Foster R, Ponting DJ, Stalford SA, Tennant RE, Thomas R. Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity data. Regulatory Toxicology and Pharmacology. 2020 Oct 1;116:104749
24. Jacobs MN, Colacci A, Corvi R, Vaccari M, Aguila MC, Corvaro M, Delrue N, Desaulniers D, Ertych N, Jacobs A, Luijten M. Chemical carcinogen safety testing: OECD expert group international consensus on the development of an integrated approach for the testing and assessment of chemical non-genotoxic carcinogens. Archives of toxicology. 2020 Aug;94:2899-923.
25. Ismail M, Akhtar K, Khan MI, Kamal T, Khan MA, M Asiri A, Seo J, Khan SB. Pollution, toxicity and carcinogenicity of organic dyes and their catalytic bio-remediation. Current pharmaceutical design. 2019 Sep 1;25(34):3645-63.
26. Becker RW, Ibáñez M, Lumbaque EC, Wilde ML, da Rosa TF, Hernández F, Sirtori C. Investigation of pharmaceuticals and their metabolites in Brazilian hospital wastewater by LC-QTOF MS screening combined with a preliminary exposure and in silico risk assessment. Science of The Total Environment. 2020 Jan 10;699:134218.
27. Vyas AJ, Godhaniya JP, Patel AI, Patel AB, Patel NK, Chudasama A, Shah SR. A review on carcinogenic impurities found in marketed drugs and strategies for its determination by analytical methods. Asian Journal of Pharmaceutical Analysis. 2021;11(2):159-69.
28. Patel AB, Asnani AH, Vyas AJ, Patel NK, Patel AI, Lumbhani DA. A brief review on genotoxic impurities in pharmaceuticals. Asian Journal of Pharmaceutical Research. 2021;11(3):187-93.
29. Vitorino JD, Costa PM. After a century of research into environmental mutagens and carcinogens, Where Do We Stand?. International Journal of Environmental Research and Public Health. 2023 Jan 6;20(2):1040.
30. Wichitnithad W, Nantaphol S, Noppakhunsomboon K, Rojsitthisak P. An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals. Saudi Pharmaceutical Journal. 2023 Feb 1;31(2):295-311.
31. Dasharathy S, Arjunan S, MaliyurBasavaraju A, Murugasen V, Ramachandran S, Keshav R, Murugan R. Mutagenic, carcinogenic, and teratogenic effect of heavy metals. Evidence-Based Complementary and Alternative Medicine. 2022;2022(1):8011953.
32. Gozukirmizi N, Karlık E. Short-term mutagenicity and carcinogenicity tests. Zeugma Biological Science. 2020;1(1):1-5.
33. Thresher A, Foster R, Ponting DJ, Stalford SA, Tennant RE, Thomas R. Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity data. Regulatory Toxicology and Pharmacology. 2020 Oct 1;116:104749.
34. Kobets T, Iatropoulos MJ, Williams GM. Mechanisms of DNA-reactive and epigenetic chemical carcinogens: applications to carcinogenicity testing and risk assessment. Toxicology Research. 2019 Mar 1;8(2):123-45.
35. Zeiger E. The test that changed the world: The Ames test and the regulation of chemicals. Mutation Research/Genetic Toxicology and Environmental Mutagenesis. 2019 May 1;841:43-8.
36. Marchetti F, Cardoso R, Chen CL, Douglas GR, Elloway J, Escobar PA, Harper Jr T, Heflich RH, Kidd D, Lynch AM, Myers MB. Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing. Nature Reviews Drug Discovery. 2023 Mar;22(3):165-6.
37. Doe JE, Boobis AR, Cohen SM, Dellarco VL, Fenner-Crisp PA, Moretto A, Pastoor TP, Schoeny RS, Seed JG, Wolf DC. A new approach to the classification of carcinogenicity. Archives of

Toxicology. 2022 Sep;96(9):2419- Klapacz J, Gollapudi BB. Considerations for the use of mutation as a regulatory endpoint in risk assessment. Environmental and molecular mutagenesis. 2020 Jan;61(1):84-93.28.

38. Benigni R, Bassan A, Pavan M. In silico models for genotoxicity and drug regulation. Expert Opinion on Drug Metabolism & Toxicology. 2020 Aug 2;16(8):651-62.
39. Vettorazzi A, Lopez de Cerain A, Sanz-Serrano J, Gil AG, Azqueta A. European regulatory framework and safety assessment of food-related bioactive compounds. Nutrients. 2020 Feb 26;12(3):613.
40. Felter SP, Bhat VS, Botham PA, Bussard DA, Casey W, Hayes AW, Hilton GM, Magurany KA, Sauer UG, Ohanian EV. Assessing chemical carcinogenicity: hazard identification, classification, and risk assessment. Insight from a Toxicology Forum state-of-the-science workshop. Critical Reviews in Toxicology. 2021 Sep 14;51(8):653-94.
41. Chepelev N, Long AS, Beal M, Barton-Maclaren T, Johnson G, Dearfield KL, Roberts DJ, van Benthem J, White P. Establishing a quantitative framework for regulatory interpretation of genetic toxicity dose–response data: Margin of exposure case study of 48 compounds with both in vivo mutagenicity and carcinogenicity dose–response data. Environmental and Molecular Mutagenesis. 2023 Jan;64(1):4-15.
42. Roberts SW, Lennard A, Mohan G, Bernstein J, Cauchon NS, Cole S, Curristin N, Huynh-Ba K, Kolz CN, Murti C, Tang K. Meeting report: N-nitrosamine impurity control strategies in the pharmaceutical and biotechnology industries.
43. Horne S, Vera MD, Nagavelli LR, Sayeed VA, Heckman L, Johnson D, Berger D, Yip YY, Krahn CL, Sizukusa LO, Rocha NF. Regulatory experiences with root causes and risk factors for nitrosamine impurities in pharmaceuticals. Journal of pharmaceutical sciences. 2023 May 1;112(5):1166-82.
44. Dattatraya JP, Arun SN, Deshmukh VK, Ghawate VG, Pund AR. A review on nitrosamine impurities present in drugs. Pharmaceutical Resonance. 2022.
45. Rose U. European pharmacopoeia activities on control of nitrosamines and other DNA-reactive impurities. Journal of Pharmaceutical Sciences. 2023 May 1;112(5):1163-5.